China Pharma Holdings (CPHI) Payables (2010 - 2026)

China Pharma Holdings has reported Payables for 17 years, with the latest figure at $4.1 million in Q1 2026.

• For the quarter ending Q1 2026, Payables rose 22.8% year-over-year to $4.1 million; the trailing twelve-month figure through Mar 2026 stood at $4.1 million (up 22.8% YoY), and the FY2025 full-year result was $4.0 million, up 191.82% from the prior year.
• Payables for Q1 2026 stood at $4.1 million, up from $4.0 million in the prior quarter.
• The five-year high for Payables was $6.4 million in Q3 2022, with the low at $349805.0 in Q2 2022.
• Historically, Payables has averaged $2.9 million across 5 years, with a median of $2.6 million in 2024.
• Annual changes were most pronounced in 2023 — Payables surged 1211.67% — and 2024, when it plunged 87.98%.
• China Pharma Holdings' Payables stood at $4.5 million in 2022, then retreated by 23.52% to $3.4 million in 2023, then slumped by 59.9% to $1.4 million in 2024, then soared by 191.82% to $4.0 million in 2025, then advanced by 1.48% to $4.1 million in 2026.
• The last three Payables figures came in at $4.1 million (Q1 2026), $4.0 million (Q4 2025), and $2.0 million (Q3 2025), per Business Quant data.